Flemming Lindeløv is leaving the Lundbeck Supervisory Board
Flemming Lindeløv has today informed the Supervisory Board of H.
Lundbeck A/S that he has decided to resign his duties as Chairman and
withdraw from the Lundbeck Supervisory Board as of today in order to
restore some calm around the company.
extraordinary Board meeting decided to constitute itself with Per
Wold-Olsen as new Chairman of the Board. Subsequently, Per Wold-Olsen
will take up the position of Chairman at this time and not in
connection with the Annual General Meeting as previously announced.
The Supervisory Board and Lundbeck Management will henceforth now
focus their work on Lundbeck's business and the strategic challenges
that the company is facing.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Jacob Tolstrup Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79 +45 36 43 26 38
+1 201 350 0187
Stock Exchange Release No 287 - 24 August 2007
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit